The efficacy and adverse effects of prophylactic administration of Sulfamethoxazole-Trimethoprim (ST) for Pneumocystis carinii Pneumonia (PCP) were assessed in patients with connective tissue diseases (CTD) Eightly four patients who were receiving more than 40mg/day of prednisolone were entried in the present study. Patients with at least one of the two PCP risk factors (interstitial pulmonary fibrosis and lymphopenia) , were administred either one (11 patients) or two (26 patients) ST tablets/day. The remaining 47 patients who did not receive ST served as the controls. Although PCP was detected in 4.3% of the patients in the no-ST group, none of the patients who received ST developed PCP. Five of these 26 patients who received two tablets of ST/day, experienced adverse reactions. However, no adverse reactions were detected in the patients who received one tablet of ST/day (p<0.05). Abnormal laboratory data were obtained for 10 (38.5%) of the patients who received two tablets of ST/day and for 4 (36.4%) of the 11 patients who received one tablet of ST/day. The results of the present study suggest that the prophylactic administration of one tablets of ST in patients with CTD that have at least one of the two PCP risk factors is effective in preventing PCP.
Introduction
Pneumocystis carinii Pneumonia (PCP) affects immunocompromised patients, such as those with acquired immunodeficiency syndrome (AIDS) 1), or autoimmune diseases such as connective tissue diseases (CTD) 2). PCP has one of the highest mortality rates among infectious diseases3)4). Statistical Analysis. We evaluated the differences between the two groups using the Chi-square test.
A score of p<0.05 was considered as significant. Abnormal laboratory data in the ST administration group was also analyzed (Table 5 ). Abnormal laboratory data was defined as any data that deviated from the reference ranges established by our hospital, including abnormal laboratory data detected before ST administration and that appeared to be exacerbated by ST administration. In the 1T administration group, leukopenia was seen in two SLE patients, while elevated GOT and GPT levels and hyperbilirubinemia were seen in two DM patients. The Low-dose ST administration (2-4 tablets/day) has been successfully used to prevent PCP in AIDS patients, patients with hematological neoplastic diseases, and patients receiving immunosupressants after kidney transplantations16)17). Many reports have documented the effective use of ST in preventing the onset of PCP in AIDS patients10)16)18)19). In one study, a very high efficacy rate was reported: not a single case of PCP occurred in 981 patient-months17). However the overall incidence of adverse reactions (mostly rash and gastrointestinal tract disorders) was also high (56%). In the present study, none of the CTD patients who received ST developed PCP. Despite the numerous differences between AIDS and CTD, the prophylactic administration of ST appears to be effective in preventing PCP to some degree in both AIDS and CTD patients. However, the incidence of adverse reactions in the present study was lower than that encountered in AIDS patients. The adverse reactions in the CTD patients were also less severe and more diverse. These differences are probably related to the differences in the underlying diseases.
Drugs with sulfonamines radicals, such as ST, have been shown to induce and exacerbate SLE11). However, SLE was not exacerbated in any of the 15 patients in the present study who received ST. Although the fiequency of adverse reactions associated with ST prophylactic administration in high in CTD patients, the results of the present study suggest that the daily administration of one or two tablets of ST is relatively safe and effective in preventing PCP. In view of the frequency of adverse reactions, the daily administration of one ST tablet is recommended.
We have previously reported that in addition to the administration of immunosuppressants, the presence of IPF and lymphopenia are risk factors for PCP in CTD patients9). In the present study, ST was administred to CTD patients with either lymphopenia or IPF. In those patients who received ST, IPF was detected in 40.5% of the patients and immunosuppressants were administered to 24.3%. In those patients who did not receive ST, mild IPF was deteced in 19.1% of the patients and immunosuppressants were administered to 10.6%. Although a significantly higher number of patients had IPF in the ST administration group, none of these patients developed PCP. This result seems to strongly support the efficacy of ST as a prophylactic agent against PCP. The results of the present study demonstrate the usefulness of the administering ST to CTD patients with at least one of the previously reported PCP risk factors.
